A szulfanilureák helye a 2-es típusú diabetes vércukorszint-csökkentö kezelésében

Translated title of the contribution: The place of sulphonylurea compounds in the blood glucose lowering therapy of type 2 diabetes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The mechanism of blood glucose lowering action of sulphonylureas, their advantages and potencial risks are overviewd in the article. The author delineates the present place of the sulphonylurea group in the antihyperglycemic therapy of type 2 diabetes, listing possibilities of monotherapeutic as well as combined applications. It is emphasized that traditional insulin-secretagogue compounds have their place in the therapy of type 2 diabetes even beside of the new, incretin-type secretagogues.

Original languageHungarian
Pages (from-to)345-349
Number of pages5
JournalLege Artis Medicinae
Volume21
Issue number5
Publication statusPublished - May 2011

Fingerprint

Sulfonylurea Compounds
Type 2 Diabetes Mellitus
Blood Glucose
Incretins
Hypoglycemic Agents
Insulin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A szulfanilureák helye a 2-es típusú diabetes vércukorszint-csökkentö kezelésében. / Winkler, G.

In: Lege Artis Medicinae, Vol. 21, No. 5, 05.2011, p. 345-349.

Research output: Contribution to journalArticle

@article{d425120798ba486a8b37eca6617f0dee,
title = "A szulfanilure{\'a}k helye a 2-es t{\'i}pus{\'u} diabetes v{\'e}rcukorszint-cs{\"o}kkent{\"o} kezel{\'e}s{\'e}ben",
abstract = "The mechanism of blood glucose lowering action of sulphonylureas, their advantages and potencial risks are overviewd in the article. The author delineates the present place of the sulphonylurea group in the antihyperglycemic therapy of type 2 diabetes, listing possibilities of monotherapeutic as well as combined applications. It is emphasized that traditional insulin-secretagogue compounds have their place in the therapy of type 2 diabetes even beside of the new, incretin-type secretagogues.",
keywords = "Cardiovascular risk, Hypoglycemia, Sulphonylurea drugs, Type 2 diabetes",
author = "G. Winkler",
year = "2011",
month = "5",
language = "Hungarian",
volume = "21",
pages = "345--349",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "5",

}

TY - JOUR

T1 - A szulfanilureák helye a 2-es típusú diabetes vércukorszint-csökkentö kezelésében

AU - Winkler, G.

PY - 2011/5

Y1 - 2011/5

N2 - The mechanism of blood glucose lowering action of sulphonylureas, their advantages and potencial risks are overviewd in the article. The author delineates the present place of the sulphonylurea group in the antihyperglycemic therapy of type 2 diabetes, listing possibilities of monotherapeutic as well as combined applications. It is emphasized that traditional insulin-secretagogue compounds have their place in the therapy of type 2 diabetes even beside of the new, incretin-type secretagogues.

AB - The mechanism of blood glucose lowering action of sulphonylureas, their advantages and potencial risks are overviewd in the article. The author delineates the present place of the sulphonylurea group in the antihyperglycemic therapy of type 2 diabetes, listing possibilities of monotherapeutic as well as combined applications. It is emphasized that traditional insulin-secretagogue compounds have their place in the therapy of type 2 diabetes even beside of the new, incretin-type secretagogues.

KW - Cardiovascular risk

KW - Hypoglycemia

KW - Sulphonylurea drugs

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79958842023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958842023&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 345

EP - 349

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 5

ER -